In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

We use cookies to optimise the design of this website and make continuous improvement. By continuing your visit, you consent to the use of cookies. Learn more

2012 ESC Guidelines overview

Session presentations
Basic Sciences, Pharmacology, Genomics and Cardiovascular Pathology


During this session, the 6 new ESC guidelines for 2012 were presented.

The first presentation included the new guideline on cardiovascular disease prevention. This guideline was presented by professor Joep Perk (Sweden), who highlighted that of all deaths that occur in Europe before the age of 75 years, 42% in women are due to cardiovascular disease and 38% in men. Conversely, 50% of the reductions in cardiovascular mortality are due to reduction in risk factors and 40% due to improved treatments. The current new guideline has been accomplished with various different societies and has put forward important emphasis and recommendations on improvement in risk factors.

The second guideline concerned heart failure. Professor John McMurray (UK) indicated that the new guideline linked recommendations to treatment effects. Specifically, new information was provided on innovations in pharmaceutical and device therapy, but also on improved diagnostic and prognostic assessment (with advanced biomarkers and imaging modalities). Also, clear definitions on systolic versus diastolic heart failure were included.

The third presentation addressed the new guideline on STEMI, and was presented by the co-chairs professors Stefan James (Sweden) and Gabriel Steg (France). The presenters highlighted the improvements in early diagnosis, prehospital logistics of care and better treatment definition in cardiac arrest. Also, they eluded on the modifications on maximal time delays and the timing of angiography after thrombolysis. They also discussed on stent recommendations and anti-thrombotic therapy.

The fourth presentation concerned the 3rd universal definition of myocardial infarction, chaired by professors Joseph Alpert (USA), Kristian Thygesen (Denmark) and Harvey White (New Zealand); this task force is a collaboration between different associations from the USA, Europe and Asia. This presentation was organized along the improved definitions of the 5 types of myocardial infarction and their clinical implications.

The fifth guideline was on valvular disease, highlighting a collaboration between the European Association of CardioThoracic Surgery (EACTS) and the ESC. The presentation was initiated by professor Alec Vahanian (France) addressing the new recommendations in aortic valve disease, and (for the first time) with recommendations on TAVI. The second part was presented by professor Ottavio Alfieri (Italy) on the novel and expanded recommendations in mitral (and tricuspid) valve disease.

The sixth and last presentation concerned the short update on atrial fibrillation, presented by professor John Camm (UK); the main highlights included the recommendations on the use of novel oral anticoagulations, modified recommendations in anti-arrhythmic therapy and suggestions for the role of catheter ablation.

References


750

SessionTitle:

2012 Guidelines overview

The content of this article reflects the personal opinion of the author/s and is not necessarily the official position of the European Society of Cardiology.